Dioguard™ Frequently Asked Questions

1. Who is Diomics?

Diomics Corporation is a biotechnology company focused on science-based innovation and the development of life-improving products. Our proprietary Diomat™ technology platform is optimized for the collection and delivery of compounds and proteins and can also be used for drug delivery, long-term monitoring, diagnostics and production of life-saving hormones and other bio-compounds. Based in San Diego, California, Diomics has developed numerous products, tools and services for the molecular, diagnostic and forensic industries.

2. What is Diomat?

Diomat is a proprietary, bioresorbable material manufactured from an FDA-approved synthetic biopolymer that is commonly used in tissue growth, rhinoplasty, wound care and other procedures. It can be formed into a variety of shapes and sizes, from nano-sized beads for delivering antibodies or drug therapy, to films, gauzes, swabs and 3D-printed shapes. Diomat’s extreme level of hydrophilicity gives it a unique ability to bind tightly to antibodies, proteins and compounds, allowing for extended duration of residence in a specific part of the body and controlled release of the antibody or other active ingredient over time before being safely absorbed and naturally excreted.

3. What is Dioguard™?

The Dioguard prophylactic spray is an easy-to-administer nasal spray, currently undergoing in vitro testing, that pairs Diomics’ proprietary synthetic biopolymer material with human IgG monoclonal antibodies to create a protective shield in the nasal cavity, the entry point for SARS-Cov-2.

4. How does Dioguard work?

Nanosized biopolymer beads deliver monoclonal antibody protection against COVID-19 by creating a shield of antibodies in the nasal cavity that capture, bind to, and neutralize the SARS-CoV-2 virus before it can reach and enter the cells that cause infection. 

5.How long will Dioguard last?

Baseline testing for how long the protective spray will remain in the nasal cavity is currently underway. It is anticipated the material will remain in the mucosal lining for 24-36 hours.

6. Where do the antibodies that you are using come from?

Dioguard is comprised of human IgG monoclonal antibodies licensed from Carlsbad-based, Active Motif, Inc., a leader in epigenetic research. 

Active Motif researchers at a leading university hospital obtained blood plasma from eleven adult patients who had recovered from Covid-19 in Wuhan, China. The plasma contained thousands of antibodies produces by their immune systems as they battled the infection. From the eleven antibodies that held out the greatest promise of protection, one antibody stood out. 414-1. This antibody is potent enough to neutralize SARS-CoV-2 virus particles with 98 percent effectiveness. 

This is the antibody being paired with Diomics’ biocompatible, bioresorbable polymer, called Diomat.

7. Who is Active Motif?

Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigeneticsbased research tools to analyze nuclear function. Its customers include life scientists from academic and government institutions, biotechnology and pharmaceutical companies, hospitals, and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, California, and offices in Shanghai, China; Tokyo, Japan; and Waterloo, Belgium. Active Motif applies a multi-disciplinary approach to create new and modify existing technologies to meet the current and future needs of life science researchers.

8. What happens to the neutralized virus?

Once the virus is trapped by the antibodies, it is absorbed through the mucosal lining into the body, processed through the Krebs Cycle, and eliminated.

9. How do you anticipate Dioguard being used?

We envision people using Dioguard as a prophylactic assurance when entering public spaces such as schools, airports, hospitals and any other high traffic environments. It will fill the void of protection for those who have not been vaccinated, as well as those who have been vaccinated but have not yet produced sufficient antibodies to be safe from the virus. In addition, using the spray may significantly reduce shedding of previously inhaled virus particles, potentially lowering the risk of an asymptomatic person infecting others near them.

10. Will Dioguard be available over the counter?

Commercialization of the patch is currently being explored. Availability for OTC will depend on FDA approval.

11. How much will Dioguard cost?

Our goal is to ensure that the patch is as widely accessible as possible, so we’re laserfocused on creating efficient, cost-effective manufacturing and distribution strategies and pricing that respond not just to the demands of the marketplace but to the broader needs of society as well. 

12. What is the status of clinical trials for Dioguard?

 Dioguard is currently in In Vitro testing. Once complete, the fast-tracked trials will move to In Vivo testing.